Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic

Riad, Abanoub; Pokorná, Andrea; Attia, Sameh; Klugarová, Jitka; Koščík, Michal; Klugar, Miloslav

doi:10.3390/jcm10071428

Cited by 303 publications

(427 citation statements)

References 28 publications

Supporting

Mentioning

329

Contrasting

Unclassified

Order By: Relevance

“…The overall prevalence of CoronaVac SEs in this independent study (local: 42.2% and systemic: 40.6%) is significantly lower than mRNA vaccines SEs reported by the Centers for Disease Control and Prevention (CDC) based on phase III trials, Pfizer-BioNTech (local: 84.7% and systemic: 77.4%) and Moderna (local: 86% and systemic: 66.6%) [23,24]. This is also supported by the findings of our independent study of Pfizer-BioNTech COVID-19 vaccine SEs, which showed that 93.1% of all vaccinated healthcare workers in the Czech Republic experienced at least one SE either locally or systemically [17]. Moreover, the SE prevalence of viral vector vaccine of AstraZeneca-Oxford reported by the European Medicines Agency (EMA) was considerably higher than CoronaVac [25].…”

Section: Discussionsupporting

confidence: 55%

See 1 more Smart Citation

Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey

Riad

Sağıroğlu

Üstün

et al. 2021

JCM

Self Cite

103

View full text Add to dashboard Cite

Background: COVID-19 vaccine hesitancy is a serious threat to mass vaccination strategies that need to be accelerated currently in order to achieve a substantial level of community immunity. Independent (non-sponsored) studies have a great potential to enhance public confidence in vaccines and accelerate their uptake process. Methods: A nationwide cross-sectional study for the side effects (SE) of CoronaVac was carried out in February 2021 among Turkish healthcare workers who were recently vaccinated. The questionnaire inquired about local and systemic SEs that occurred in the short-term, within four weeks, following vaccination. Results: A total of 780 healthcare workers were included in this study; 62.5% of them experienced at least one SE. Injection site pain (41.5%) was the most common local SE, while fatigue (23.6%), headache (18.7%), muscle pain (11.2%) and joint pain (5.9%) were the common systemic SEs. Female healthcare workers (67.9%) were significantly more affected by local and systemic SEs than male colleagues (51.4%). Younger age, previous infection, and compromised health status (chronic illnesses and regular medicines uptake) can be associated with an increased risk of CoronaVac SEs; Conclusions: The independent research shows a higher prevalence of CoronaVac SEs than what is reported by phase I–III clinical trials. In general, the results of this study confirm the overall safety of CoronaVac and suggest potential risk factors for its SEs. Gender-based differences and SEs distribution among age groups are worth further investigation.

show abstract

Section: Discussionsupporting

confidence: 55%

“…The fourth section explored the short-term local and systemic SEs that emerged after receiving the CoronaVac COVID-19 vaccine (the questionnaire is in Table S1). The validation process and psychometric properties of the questionnaire were previously reported in detail [17].…”

Section: Instrumentmentioning

confidence: 99%

Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey

Riad

Sağıroğlu

Üstün

et al. 2021

JCM

Self Cite

103

View full text Add to dashboard Cite

show abstract

“…Most of studies have assessed mainly the post-vaccination adverse reactions of the Pfizer-BioNTech, Moderna, and Astrazeneca vaccines [21,22,23,24,25], while only two studies focus on Sinopharm COVID-19 vaccine [16,17], There are no published studies yet that have focused on Sinopharm COVID-19 vaccine side effects in UAE.…”

Section: Discussionmentioning

confidence: 99%

Side Effects and Perceptions Following Sinopharm COVID-19 Vaccination

Qubais

Al-Shahrabi

Alhaj

et al. 2021

Preprint

View full text Add to dashboard Cite

Objectives Vaccines are one of the best interventions developed for eradicating COVID-19 the rapid creation of vaccinations was increased the risk of vaccine safety problems. The aim of this study to provide evidence on Sinopharm COVID-19 vaccine side effects. Methods A cross-sectional survey study was conducted between January and April 2021 to collect data on the effects of COVID-19 vaccine among individuals in the UAE. Demographic data chronic conditions side effects of the 1st and 2nd dose toward the vaccination, and the response of unwilling taking COVID-19 vaccine were reported. Results The most common side effects of post 1st dose (less than 49 years old vs >49 years) were normal injection site pain, fatigue, and headache while pain at the vaccination site fatigue lethargy headache and tenderness were the most side effects of the post 2nd dose in both groups. All the side effects in both doses were more prevalent among the participants less than 49-year-old group. Among females vs males side effects were more common in females compared with males in both doses in both doses. The most common adverse reactions of 1st dose in (females vs males) were fatigue lethargy headache while in 2nd dose were fatigue sever injection site pain. The most common reason of not willing to take the COVID-19 vaccine were the vaccines are not effective and they were not authorized to take vaccine. Conclusion The 1st and 2nd dose post-vaccination side effects were mild predictable and there were no hospitalization cases this data will help to reduce the vaccine hesitancy.

show abstract

“…A self-administered questionnaire with 28 multiple-choice items was adapted from previous studies on influenza vaccine SEs and the authorization reports of the Centers for Disease Control and Prevention (CDC, Atlanta, GA, USA) for COVID-19 vaccines [ 18 , 29 ]. The whole process of adaptation, validation and reliability testing of the questionnaire was described in detail previously [ 25 , 30 , 31 ]. Experts panel validation and test re-test reliability were utilized to validate the suggested instrument with a mean Cohen’s kappa coefficient of 0.89 ± 0.13 (0.54–1).…”

Section: Methodsmentioning

confidence: 99%

Safety of ChAdOx1 nCoV-19 Vaccine: Independent Evidence from Two EU States

et al. 2021

Self Cite

View full text Add to dashboard Cite

Recent reports of thrombosis following AstraZeneca COVID-19 vaccine in young females (<55 years-old) led to temporary suspension and urgent investigation by the European Medicines Agency (EMA) that concluded that vaccine benefits still outweigh its side effects (SEs). Therefore, this study aims to provide early independent evidence on the vaccine SEs’ prevalence and their potential risk factors; a cross-sectional survey-based study was carried out between February and March 2021 in Germany and Czech Republic among healthcare workers who recently received the AstraZeneca COVID-19 vaccine. The study used a validated self-administered questionnaire composed of twenty-eight multiple-choice items covering demographic variables, medical anamneses, and local, systemic, oral, and skin related SEs of the vaccine. Out of the ninety-two included participants, 77.2% were females and 79.3% were from Germany. Their mean age was 35.37 ± 12.62 (19–64) years-old, 15.2% had chronic illnesses and 22.8% were receiving medical treatments. Overall, 94.6% of the participants reported at least one SE. The most common local SE was injection site pain (72.8%), and the most common systemic SEs were fatigue (73.9%), muscle pain (55.4%), chills (48.9%), feeling unwell (46.7%), nausea (45.7%), and headache (29.3%). The vast majority (91.9%) resolved within 1–3 days, and the below 35 years-old group was the least affected age group. The SEs’ frequency was insignificantly higher in females and previously infected participants; the vaccine safety for the elderly was supported by the early findings of this study. Chronic illnesses and medical treatments were not associated with an increased risk of SE incidence and frequency. No blood disorder SEs were reported in our sample. Further independent studies are highly required to evaluate the safety of the AstraZeneca vaccine and to explore whether gender or previous infection could be associated with the vaccine SEs.

show abstract

Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic

Cited by 303 publications

References 28 publications

Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey

Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey

Side Effects and Perceptions Following Sinopharm COVID-19 Vaccination

Safety of ChAdOx1 nCoV-19 Vaccine: Independent Evidence from Two EU States

Contact Info

Product

Resources

About